Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome

Despite recent achievements in secondary cardiovascular prevention, the risk of further events in patients with chronic coronary syndromes (CCS) remains elevated. Highest risk is seen in patients with recurrent events, comorbidities or multisite atherosclerosis. Optimising antithrombotic strategies...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 140; p. 111783
Main Authors Patti, Giuseppe, Fattirolli, Francesco, De Luca, Leonardo, Renda, Giulia, Marcucci, Rossella, Parodi, Guido, Perna, Gian Piero, Andreotti, Felicita, Ghiglieno, Chiara, Fedele, Francesco, Marchionni, Niccolò
Format Journal Article
LanguageEnglish
Published Elsevier Masson SAS 01.08.2021
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite recent achievements in secondary cardiovascular prevention, the risk of further events in patients with chronic coronary syndromes (CCS) remains elevated. Highest risk is seen in patients with recurrent events, comorbidities or multisite atherosclerosis. Optimising antithrombotic strategies in this setting may significantly improve outcomes. The higher the baseline risk, the higher the absolute event reduction with approaches using combined antithrombotic treatments. Tailoring such strategies to the individual patient risk appears crucial to achieve net benefit (i.e., substantial ischaemic event prevention at a limited cost in terms of bleeding). This paper focuses on antithrombotic and non-pharmacological approaches to secondary cardiovascular disease prevention in CCS. In particular, we critically review current evidence on the use of dual antithrombotic therapy, including the newest approach of aspirin plus low-dose anticoagulation and its net clinical outcome according to baseline risk. •The risk of recurrent events remains high in patients with CCS.•Antithrombotic approaches are SAPT or DAPT or low-dose rivaroxaban plus aspirin.•An antithrombotic approach tailored to both ischaemic and bleeding risk is crucial.•Healthy lifestyle and risk factor control further decrease recurrent events.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2021.111783